FAC traded down -9.57% at $5.20 during regular trading on Aug. 14, a -$0.55 move from the prior close of $5.75. Premarket action was only modestly lower near -0.87%, so the bulk of the selling emerged after the open and intensified into midday.

BLSH is trading down -10.55% at $24.58 during Friday's regular session, versus a previous close of $27.48. The slide follows Rosenblatt Securities cutting its BLSH price target to $30 from $42.50 while keeping a Neutral rating, citing weak third-quarter trading activity and likely downward consensus revisions.

IMC is down -22.43% at $7.84 during regular trading, reversing from a $10.10 prior close and a $9.80 open. The decline follows the prior session’s +26.25% surge to a 52-week high of $11.10, triggering sharp profit-taking.

Target in focus: Strategy Inc. (NASDAQ: MSTR ) currently trades near $92, and investors are asking whether the stock can reclaim the $200 level — a psychologically significant round number it last touched in May 2026. Strongest bullish factor: Strategy holds over 843,000 Bitcoin (BTC), making it the world's largest corporate BTC holder. Any sustained Bitcoin rally would directly lift the value of its treasury and likely drive the stock higher.

INO is up +13.33% during Friday’s regular session, trading near $1.02 versus Thursday’s close of $0.90. The move is primarily a continuation of Thursday’s post-earnings, analyst-upgrade momentum rather than a fresh company-specific headline.

The central question is whether Xencor, Inc. ( XNCR ) can reach a $30 stock price target , roughly 30% above recent trading near $23. The strongest bullish factor is operational momentum: second-quarter results beat expectations by a wide margin, and several clinical catalysts are approaching.

Xencor’s XmAb protein engineering platform positions the company for potential advances in bispecific antibody therapies targeting cancer and autoimmune diseases, with multiple programs in clinical development. Upcoming clinical data readouts and regulatory milestones for candidates such as XmAb942 in inflammatory bowel disease (IBD) represent key near-term catalysts that could influence investor sentiment.

XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August. The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.

INO is trading up +2.42% at $0.9219 during regular market hours as of roughly 10:09 a.m. ET, compared with Thursday’s close of $0.9001. The advance extends Thursday’s +16.90% jump after Jefferies upgraded Inovio to Buy from Hold and raised its price target to $3.00 from $1.80 on positive FDA review progress for INO-3107.

HeartFlow shares are up +25.64% in regular trading Friday at $38.96, versus the prior close of $31.01. The move extends an after-hours surge following Q2 results: revenue rose +48% year-over-year to $64.1 million, beating forecasts, and adjusted loss per share of -$0.07 was much narrower than expected.

NU is trading up +13.07% at $15.75 in early regular trading, extending an after-hours/premarket surge after Q2 results were released following Thursday's close. Primary catalyst: Q2 2026 net income reached a record $1.06 billion, its first billion-dollar quarter, up +49% year over year and above consensus; revenue rose +39% to $5.88 billion.

ENHA is down -18.00% during regular trading on Aug. 14, sliding to about $2.05 from a prior close of $2.50. The selloff follows Q2 results released after the Aug. 13 close, with revenue of $17.71M missing expectations by $6.89M and GAAP EPS of -$0.53.

MRLN fell -16.74% in Friday's regular session to $3.68, down from Wednesday's close of $4.42. The drop follows Q2 2026 results reported after Wednesday's close: revenue of about $2.2 million missed the roughly $3.8 million consensus, and an adjusted loss of $1.11 per share was far wider than the $0.28 expected.

KinderCare Learning (KLC) is down -26.50% to $3.55 in early regular trading, extending losses that began after-hours Wednesday. The selloff follows Q2 adjusted EPS of $0.08, missing the $0.10 consensus, with revenue down -0.4% YoY to $697.5M.

YSS is down -11.03% to $10.24 in early regular trading on Aug. 14, versus a prior close of $11.51. The decline extends a post-earnings selloff that began after the Aug. 13 close and steepened in premarket trading, where shares fell roughly -15% at the lows.

ARS Pharmaceuticals (SPRY) is trading down -10.25% at $5.48 in early regular trading, versus a $6.10 close on Aug 13. The move follows Q2 results released after the prior close: EPS came in at -$0.63, missing the -$0.50 consensus, while revenue of $33.7M beat the $31.5M estimate.

Modular Medical (MODD) closed at $1.87 on August 13, 2026, down approximately 57% from the $4.31 closing price recorded 30 calendar days earlier on July 14, 2026. The decline has pushed the stock toward the lower end of its 52-week range of $1.74–$30.00 and well below its 50-day moving average near $3.64.

Nuwellis shares closed at $1.30 on August 13, 2026, down from $3.12 on July 15, 2026, a decline of approximately 58% over the last 30 days. The selloff was driven primarily by dilutive capital-raising activity, including a registered direct offering priced at $2.59 per share on July 31, 2026, and warrant exercise proceeds.

SNWV fell approximately 60% over the last 30 days, from a closing price of $11.96 on July 14, 2026, to $4.77 on August 13, 2026. Second-quarter 2026 revenue of $9.7 million declined 3% year over year and missed consensus estimates near $11.5 million, while the company swung to a net loss of $0.7 million.

NIVF shares fell roughly 59.9% over the 30 days through the August 13, 2026 close, declining from $1.37 to about $0.55. The move extends a deeper downtrend, with the stock down approximately 79.6% over the trailing three months.